Business Wire

Mary Kay Expands Into Kyrgyzstan, Further Elevating Beauty and Empowerment Around the World

19.9.2024 20:03:00 EEST | Business Wire | Press release

Share

Mary Kay Inc., a global leader in skin care and cosmetics, is proud to announce its expansion into Kyrgyzstan, marking a significant milestone in its ongoing international growth strategy. This exciting development underscores Mary Kay’s commitment to empowering women and providing innovative, high-quality skincare and beauty products across the globe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240919159057/en/

Mary Kay’s expansion into Kyrgyzstan marks another step forward in the company’s mission to enrich women’s lives around the world, offering top-tier beauty products and unparalleled business opportunities. (Photo: Mary Kay Inc.)

The beauty and personal care market is experiencing robust growth internationally, with sales volume in these categories almost doubling over the past several years. The beauty market is expected to reach approximately $580 billion by 2027, growing by a projected 6 percent per year1 while the direct selling market size is estimated to reach $286.7 billion by 20282. This phenomenal growth is due to more individuals turning to entrepreneurship and seeking flexible and rewarding business opportunities. Recognizing this upward trend, Mary Kay has strategically expanded into Kyrgyzstan to meet the increasing demand for premium beauty products and entrepreneurial opportunities.

“I’m confident our expansion into Kyrgyzstan will inspire countless women to discover the transformative power of Mary Kay’s award-winning products and strengthen our position as the #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World3,” said Tara Eustace, President of Mary Kay Europe Region. “Mary Kay Ash often said we’re doing far more than just selling cosmetics—we’re changing lives. This belief is at the heart of everything we do, and I am excited to witness the incredible impact we will have on the women of Kyrgyzstan.”

Mary Kay Kyrgyzstan’s operations will be managed from the Mary Kay Kazakhstan offices in Almaty, ensuring seamless integration and support for the new market. Konstantin Kulinitch, General Manager of Mary Kay Kazakhstan, shared his enthusiasm: “We are excited to extend our operations into Kyrgyzstan, where we see tremendous potential for growth. Our team in Almaty is committed to providing the best possible support to our Independent Beauty Consultants in Kyrgyzstan, helping them build successful businesses, and achieve their dreams.”

To celebrate this significant expansion, Mary Kay hosted a series of events in Bishkek, the capital of Kyrgyzstan, introducing consumers to the brand’s renowned skin care, color cosmetics, and fragrances. These events also highlighted the unique business opportunity that Mary Kay offers, empowering individuals to take control of their futures.

Mary Kay’s expansion into Kyrgyzstan marks another step forward in the company’s mission to enrich women’s lives around the world, offering top-tier beauty products and unparalleled business opportunities.

For more information about Mary Kay's global operations, leadership, mission, and commitment to enriching women’s lives, please visit www.marykayglobal.com.

About Mary Kay

Then. Now. Always. One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty brand in Texas in 1963 with one goal: to enrich women’s lives. That dream has blossomed into a global company with millions of independent sales force members in more than 35 countries. For 60 years, the Mary Kay opportunity has empowered women to define their own futures through education, mentorship, advocacy, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in preserving our planet for future generations, protecting women impacted by cancer and domestic abuse, and encouraging youth to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn, or follow us on X (formerly Twitter).

_______________________
1 McKinsey and Company. (May 22, 2023). The beauty market in 2023: A special State of Fashion report
2 Grand View Research, Inc. (July 11, 2022). Direct Selling Market Size Worth $286.7 Billion by 2028
3 “Source Euromonitor International Limited; Beauty and Personal Care 2024Edition, value sales at RSP, 2023data”

View source version on businesswire.com: https://www.businesswire.com/news/home/20240919159057/en/

Contacts

Mary Kay Inc. Corporate Communications
marykay.com/newsroom -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fmarykay.com%2Fn
ewsroom&esheet=54124254&newsitemid=20240919159057&lan=en-US&anchor=marykay.com%2
Fnewsroom&index=12&md5=1bb4233e697b42db9802a2736c1b929d
972.687.5332 or media@mkcorp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye